» Articles » PMID: 35672316

Enhanced BRAF Engagement by NRAS Mutants Capable of Promoting Melanoma Initiation

Abstract

A distinct profile of NRAS mutants is observed in each tumor type. It is unclear whether these profiles are determined by mutagenic events or functional differences between NRAS oncoproteins. Here, we establish functional hallmarks of NRAS mutants enriched in human melanoma. We generate eight conditional, knock-in mouse models and show that rare melanoma mutants (NRAS G12D, G13D, G13R, Q61H, and Q61P) are poor drivers of spontaneous melanoma formation, whereas common melanoma mutants (NRAS Q61R, Q61K, or Q61L) induce rapid tumor onset with high penetrance. Molecular dynamics simulations, combined with cell-based protein-protein interaction studies, reveal that melanomagenic NRAS mutants form intramolecular contacts that enhance BRAF binding affinity, BRAF-CRAF heterodimer formation, and MAPK > ERK signaling. Along with the allelic series of conditional mouse models we describe, these results establish a mechanistic basis for the enrichment of specific NRAS mutants in human melanoma.

Citing Articles

Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.

Wen Y, Wang H, Yang X, Zhu Y, Li M, Ma X Nat Commun. 2024; 15(1):10088.

PMID: 39572526 PMC: 11582648. DOI: 10.1038/s41467-024-54140-1.


Current Insights into the Role of UV Radiation-Induced Oxidative Stress in Melanoma Pathogenesis.

Gieniusz E, Skrzydlewska E, Luczaj W Int J Mol Sci. 2024; 25(21).

PMID: 39519202 PMC: 11546485. DOI: 10.3390/ijms252111651.


Inhibition and degradation of NRAS with a pan-NRAS monobody.

Whaby M, Ketavarapu G, Koide A, Mazzei M, Mintoo M, Glasser E Oncogene. 2024; 43(48):3489-3497.

PMID: 39379700 PMC: 11584388. DOI: 10.1038/s41388-024-03186-y.


Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?.

Healy F, Turner A, Marensi V, MacEwan D Front Pharmacol. 2024; 15:1441938.

PMID: 39372214 PMC: 11450236. DOI: 10.3389/fphar.2024.1441938.


Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma.

Goetz A, Shanahan F, Brooks L, Lin E, Mroue R, Dela Cruz D Cancers (Basel). 2024; 16(16).

PMID: 39199684 PMC: 11353013. DOI: 10.3390/cancers16162914.


References
1.
Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

2.
Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P . KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016; 7:e157. PMC: 4822095. DOI: 10.1038/ctg.2016.18. View

3.
Bremner R, Balmain A . Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell. 1990; 61(3):407-17. DOI: 10.1016/0092-8674(90)90523-h. View

4.
Nan X, Tamguney T, Collisson E, Lin L, Pitt C, Galeas J . Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015; 112(26):7996-8001. PMC: 4491781. DOI: 10.1073/pnas.1509123112. View

5.
Kessler D, Bergner A, Bottcher J, Fischer G, Dobel S, Hinkel M . Drugging all RAS isoforms with one pocket. Future Med Chem. 2020; 12(21):1911-1923. DOI: 10.4155/fmc-2020-0221. View